A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

Reductions in alcohol intake noted in high and low consumers; no significant difference seen in percentage reductions for men and women. (HealthDay News) — Glucagon-like peptide-1 receptor agonists ...

Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its ...

New Delhi: Medications such as liraglutide or semaglutide taken for weight loss also have the potential to reduce alcohol consumption by almost two-thirds, according to new research. Alcohol use ...

The fight against obesity is one of the major challenges of 21st century medicine. This chronic disease, with its numerous ...

The intersection of pharmaceutical and food technologies presents challenges but also opportunities for ingredient suppliers and food brands. For Food Brands: Adopt bifurcated marketing strategies; ...

The MarketWatch News Department was not involved in the creation of this content. Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding ...

The GLP-1 agonists market stands at the forefront of innovation in metabolic and cardiovascular disease management. With the confluence of rising disease burden, expanding therapeutic indications, and ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug Discovery Foundation in New York City, a nonprofit group that supported earlier ...

An Ozempic-like drug implant might be available for your pets soon. Okava Pharma's GLP-1 implant pilot for obese cats (MEOW-1 ...

Data were included for 262 adults with a body mass index greater than or equal to 27kg/m2 who were initiated on liraglutide or semaglutide. HealthDay News — Glucagon-like peptide-1 receptor agonists ...